Bortezomib then pembrolizumab and cisplatin for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- Your breast cancer is triple-negative (ER-negative or very low ER) and has spread to other organs
- You have had standard chemotherapy before: anthracycline, cyclophosphamide, and a taxane (unless doxorubicin wasn’t possible for you)
- You can have up to 3 prior chemotherapy treatments for metastatic disease
- A doctor can safely take a biopsy sample from your metastatic tumor (or from skin if needed)
- Your body functions look strong enough for treatment (blood counts, liver, kidneys, and clotting tests meet limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of two drugs, bortezomib and cisplatin, for people with breast cancer that has spread or come back after standard treatments. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.